Hardman & Co

Tissue Regenix Group Dual revenue stream growth

Tissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since

Hardman & Co

Allergy Therapeutics Continuing to gain market share

Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only

Hardman & Co

ValiRx Progressing all the pipeline

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

Scancell Holdings Preparing for next clinical studies

Scancell Holdings Plc (LON:SCLP) is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity

Hardman & Co

Sinclair Pharma Demand growing in target markets

In 2016 Sinclair Pharma Plc (LON:SPH) was transformed into a streamlined, pure-play aesthetics company with a concentrated, competitive portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatments

Hardman & Co

ValiRx Positive early data from VAL401

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

The Gym Group Alternative valuation

Gym Group Plc (LON:GYM) Valuing high growth companies can be tricky. The cost of establishing growth tends to drag down current earnings, making the company look expensive on straight PE

Diversified Energy Company plc
Diversified Energy CEO Rusty Hutson discusses the Maverick Natural Resources acquisition and its impact on growth, margins, and sustainability goals.
Cerillion
In an exclusive interview with DirectorsTalk, Cerillion plc CEO Louis Hall discusses the $11.4 million telecom contract and its impact on the company's growth strategy.
Pan African Resources
Discover the success behind Pan African Resources plc and its outperformance as discussed by Gervais Williams, Co-Fund Manager of Diverse Income Trust plc.
One Health Group plc
In an exclusive interview, One Health Group plc CEO Adam Binns discusses the company's partnership with the NHS, operational growth, and future plans.
Ilika plc
In an exclusive interview, Ilika plc CEO Graeme Purdy discusses progress with Stereax & Goliath, exciting technical milestones, and competition with peers.
Arbuthnot Banking Group plc
Gervais Williams discusses Arbuthnot Banking Group plc's success and potential growth in an exclusive interview with DirectorsTalk.
Discover the latest trends in commercial real estate investment, from shifting market landscapes to emerging opportunities in private credit financing.
Volta Finance
Discover the allure of Collateralized Loan Obligations (CLOs) and how they offer high yields and structured returns to savvy investors in today's market.
Fidelity China Special Situations
China's AI sector is booming thanks to DeepSeek's breakthrough, attracting investment and reshaping the tech rivalry with the U.S. Learn more here.
Fidelity Special Values
The British Pound is gaining momentum against the US Dollar, with potential for a test of the 2025 high. Trade tensions and central banks drive volatility.
Fidelity European Trust
European markets saw a lift driven by key earnings reports, with notable movements in sectors like automobiles and financial services. Read more here.
Beeks Financial Cloud Group Plc secures Nasdaq as the latest customer for its Exchange Cloud service, solidifying its leadership in low-latency solutions.
Agronomics Limited (LON:ANIC) shapes the future of sustainable food production with strategic investments in cellular agriculture. Cavendish report highlights its progress in 2024.
SAE Renewables (LON:SAE) advances energy ambitions with £1.3M payment for Uskmouth BESS project. Analyst sees positive impact on future projects.
hVIVO plc
hVIVO plc achieves milestone with £3.2 million hLAB contract, showcasing growth in laboratory services. Read about the company's latest achievement here.
Greggs
Greggs plc (LON:GRG) shines in tough market conditions, delivering solid FY24 results with revenue of £2,014 million and strong growth.